Windward Bio successfully listed on the Nasdaq on November 13, 2026, with shares closing at $28.50, a 68% increase from the $17.00 IPO price. The clinical-stage biotechnology firm, backed by Qiming Venture Partners, currently holds a market capitalization of approximately $1.69 billion. The company is focused on developing ultra-long-acting antibody medicines for respiratory and dermatologic diseases.
Bullish
🤖 65%
Windward Bio listed on Nasdaq on November 13, 2026 at $17.00 and closed its first day at $28.50, up 68%, with a market cap of about $1.69 billion. Such a large first-day premium typically signals strong demand that can support the price in the following days as index and fund interest builds. The stock is clinical-stage with no revenue, so the premium could also fade as early investors take profits.
Catalysts
- ▲ First trading day close at $28.50 vs $17.00 IPO price (+68%) on November 13, 2026
- ▲ Market capitalization of approximately $1.69 billion at the close
Risk Factors
- ▼ Large first-day gain could reverse as IPO allocation holders lock in profits
- ▼ Clinical-stage company with no marketed products; pipeline programs still in trials